CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Homocysteine Testing in the Screening and Diagnosis and Management of Cardiovascular Disease

This policy governs coverage and medical necessity of plasma homocysteine testing for screening, evaluation, and management of cardiovascular disease (CVD) and venous thromboembolism (VTE) for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyHomocysteine Testing in the Screening and Diagnosis and Management of Cardiovascular Disease

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2024

Next Review DateN/A

Key ActionOnly the ordering physician may request authorization or handle appeals; laboratories must not obtain authorization on behalf of the ordering physician.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredMedicare Advantage

Not medically necessaryCommercial Products

RCTs & meta-analysesEvidence

2023-08-16Last reviewed

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered / Not medically necessary

Testing and indications that are NOT covered or are not medically necessary

Primary stance: Measurement of plasma homocysteine levels is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products for screening, evaluation, and management of individuals for cardiovascular disease and individuals with or at risk for venous thromboembolism.

Supported by randomized trials and meta-analyses showing homocysteine-lowering interventions do not improve cardiovascular or VTE outcomes.

Laboratories and their representatives are not permitted to obtain prior authorization on behalf of ordering physicians. Only the ordering physician may be involved in authorization, appeals, or other administrative processes related to authorization or medical necessity. If a laboratory or third party participates in the authorization process on behalf of an ordering physician, BCBSRI may treat that as a violation and take severe action up to and including termination from the provider network. Additionally, if a laboratory provides a service that has not been authorized, the service will be denied and become the financial liability of the participating laboratory and may not be billed to the member.

Routine measurement of plasma homocysteine is considered not medically necessary because randomized controlled trials and meta-analyses have consistently shown that homocysteine‑lowering interventions (for example, folate and B vitamin supplementation) do not improve major cardiovascular outcomes. A large body of placebo‑controlled RCT evidence fails to demonstrate that lowering homocysteine reduces rates of myocardial infarction, stroke, or cardiovascular death, and the findings regarding stroke were judged weak with uncertain clinical significance. Given these results, routine homocysteine testing is unlikely to lead to management that improves net health outcomes and therefore is not medically necessary for evaluation or management of cardiovascular disease.

Covered Indications

Covered when ALL of the following are met:

Context: Although homocysteine testing has been researched as part of cardiovascular risk assessment and for patients at high risk of venous thromboembolism (including idiopathic, recurrent, early-age, or unusual-site thrombosis), routine measurement of total plasma homocysteine is not supported as improving net health outcomes.

Observational studies suggested associations, but randomized controlled trials and meta-analyses have not demonstrated benefit from homocysteine-lowering interventions for major cardiovascular or VTE outcomes.

Clinical scenarios researched (not covered): Testing considered in: asymptomatic individuals for CVD risk prediction; patients with existing CVD; patients at high risk for VTE or with idiopathic/recurrent/early-age/unusual-site VTE.

These indications have been evaluated in observational studies and trials but do not demonstrate improved outcomes when acted upon.

Evidence summary: Randomized trials and meta-analyses consistently report that homocysteine‑lowering treatment (folate and/or B vitamins) does not reduce major cardiovascular events and does not reduce VTE risk; routine testing is therefore unlikely to lead to management that improves health outcomes.

Coding

Not covered CPT codesCPTNot Covered

No codes listed

Provider Actions

Note

Prior Authorization

Prior authorization: Not applicable.

Note

Documentation Required

Authorization Responsibility

Only the ordering physician shall be involved in authorization, appeal, or other administrative processes related to authorization/medical necessity. Laboratories and laboratory representatives are not permitted to obtain clinical authorization or participate on behalf of the ordering clinician. The ordering physician must complete and submit any required authorization requests and pursue any appeals.

Denial Risk

Laboratory Authorization Restrictions

If a laboratory provides a laboratory service that has not been authorized, the service will be denied and the financial liability will be the responsibility of the participating laboratory; the service may not be billed to the member. BCBSRI considers it a violation if a laboratory or third party assists or acts on behalf of the ordering physician in the authorization or appeal process and may take actions up to termination from the provider network.

Ordering Requirements

Step Therapy

ORDERING REQUIREMENTS: Authorization limited to ordering physician

Only the ordering physician may be involved in authorization and appeals; laboratories cannot obtain authorization on behalf of the ordering physician.

Background

Homocysteine is a sulfur‑containing amino acid that has been investigated as a potential risk marker for cardiovascular disease (CVD) and venous thromboembolism (VTE). Observational studies identified associations between elevated homocysteine and vascular risk, and because homocysteine concentrations inversely correlate with folate, intervening with folate/B‑vitamin therapy was studied to determine whether lowering homocysteine would reduce CVD or VTE events. However, randomized trials and meta‑analyses of these interventions generally have not demonstrated improved major cardiovascular or VTE outcomes, which informs the policy stance on testing.

Definitions

Total plasma homocysteine — definition of total plasma homocysteine

DefinitionTotal plasma homocysteine: the sum of homocysteine and its oxidized forms measured in plasma.

Biochemical contextHomocysteine is a sulfur-containing amino acid that is rapidly oxidized in plasma into homocysteine and cysteine–homocysteine disulfide.

Measurement scopeMeasurement of total plasma homocysteine includes reduced homocysteine plus its oxidized disulfide forms.

Clinical relevanceOffered as part of comprehensive cardiovascular risk assessment and for patients at high risk of venous thromboembolism (idiopathic, recurrent, young onset, or unusual site thrombosis).

Not Covered

Measurement of plasma homocysteine is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products for screening, evaluation, or management of individuals for cardiovascular disease and for individuals with or at risk for venous thromboembolism.